JP2013541576A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013541576A5 JP2013541576A5 JP2013537158A JP2013537158A JP2013541576A5 JP 2013541576 A5 JP2013541576 A5 JP 2013541576A5 JP 2013537158 A JP2013537158 A JP 2013537158A JP 2013537158 A JP2013537158 A JP 2013537158A JP 2013541576 A5 JP2013541576 A5 JP 2013541576A5
- Authority
- JP
- Japan
- Prior art keywords
- insulin
- present
- age
- treatment
- symptoms
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 108090001061 Insulin Proteins 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 201000001421 hyperglycemia Diseases 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 208000013016 Hypoglycemia Diseases 0.000 description 1
- 206010022095 Injection Site reaction Diseases 0.000 description 1
- 108010089308 Insulin Detemir Proteins 0.000 description 1
- 108010057186 Insulin Glargine Proteins 0.000 description 1
- COCFEDIXXNGUNL-RFKWWTKHSA-N Insulin glargine Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(=O)NCC(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 COCFEDIXXNGUNL-RFKWWTKHSA-N 0.000 description 1
- 208000017442 Retinal disease Diseases 0.000 description 1
- 206010038923 Retinopathy Diseases 0.000 description 1
- 206010038934 Retinopathy proliferative Diseases 0.000 description 1
- 208000030962 Subcutaneous tissue disease Diseases 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229960002869 insulin glargine Drugs 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP10190303.7 | 2010-11-08 | ||
| EP10190303 | 2010-11-08 | ||
| EP11151059 | 2011-01-17 | ||
| EP11151059.0 | 2011-01-17 | ||
| PCT/EP2011/069532 WO2012062698A1 (en) | 2010-11-08 | 2011-11-07 | Pharmaceutical composition, methods for treating and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015100121A Division JP6141907B2 (ja) | 2010-11-08 | 2015-05-15 | 医薬組成物、治療方法及びその使用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2013541576A JP2013541576A (ja) | 2013-11-14 |
| JP2013541576A5 true JP2013541576A5 (enExample) | 2014-10-23 |
Family
ID=44906182
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013537158A Pending JP2013541576A (ja) | 2010-11-08 | 2011-11-07 | 医薬組成物、治療方法及びその使用 |
| JP2015100121A Active JP6141907B2 (ja) | 2010-11-08 | 2015-05-15 | 医薬組成物、治療方法及びその使用 |
| JP2017019822A Active JP6515121B2 (ja) | 2010-11-08 | 2017-02-06 | 医薬組成物、治療方法及びその使用 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015100121A Active JP6141907B2 (ja) | 2010-11-08 | 2015-05-15 | 医薬組成物、治療方法及びその使用 |
| JP2017019822A Active JP6515121B2 (ja) | 2010-11-08 | 2017-02-06 | 医薬組成物、治療方法及びその使用 |
Country Status (31)
| Country | Link |
|---|---|
| US (6) | US20120283169A1 (enExample) |
| EP (2) | EP2637648A1 (enExample) |
| JP (3) | JP2013541576A (enExample) |
| KR (3) | KR102051285B1 (enExample) |
| CN (2) | CN103282030A (enExample) |
| AP (1) | AP2013006813A0 (enExample) |
| AR (1) | AR083787A1 (enExample) |
| AU (1) | AU2011328231B2 (enExample) |
| BR (1) | BR112013011968A2 (enExample) |
| CA (1) | CA2813661C (enExample) |
| CL (1) | CL2013001104A1 (enExample) |
| CO (1) | CO6781465A2 (enExample) |
| DK (1) | DK3539540T3 (enExample) |
| EA (1) | EA026712B1 (enExample) |
| EC (1) | ECSP13012661A (enExample) |
| ES (1) | ES3012504T3 (enExample) |
| FI (1) | FI3539540T3 (enExample) |
| HR (1) | HRP20250096T1 (enExample) |
| HU (1) | HUE070541T2 (enExample) |
| IL (1) | IL225597A0 (enExample) |
| LT (1) | LT3539540T (enExample) |
| MA (1) | MA34640B1 (enExample) |
| MX (2) | MX356491B (enExample) |
| NZ (1) | NZ608829A (enExample) |
| PE (1) | PE20140244A1 (enExample) |
| PH (2) | PH12013500809A1 (enExample) |
| PL (1) | PL3539540T3 (enExample) |
| RS (1) | RS66479B1 (enExample) |
| SG (1) | SG189249A1 (enExample) |
| SI (1) | SI3539540T1 (enExample) |
| WO (1) | WO2012062698A1 (enExample) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7772191B2 (en) | 2005-05-10 | 2010-08-10 | Boehringer Ingelheim International Gmbh | Processes for preparing of glucopyranosyl-substituted benzyl-benzene derivatives and intermediates therein |
| PE20080697A1 (es) | 2006-05-03 | 2008-08-05 | Boehringer Ingelheim Int | Derivados de benzonitrilo sustituidos con glucopiranosilo, composiciones farmaceuticas que contienen compuestos de este tipo, su uso y procedimiento para su fabricacion |
| PE20090938A1 (es) | 2007-08-16 | 2009-08-08 | Boehringer Ingelheim Int | Composicion farmaceutica que comprende un derivado de benceno sustituido con glucopiranosilo |
| MX339194B (es) | 2009-02-13 | 2016-05-16 | Boehringer Ingelheim Int | Composicion farmaceutica que comprende un inhibidor de sglt2, un inhibidor de dpp-iv y opcionalmente otro agente antidiabetico, y usos de la misma. |
| KR20110118668A (ko) | 2009-02-13 | 2011-10-31 | 베링거 인겔하임 인터내셔날 게엠베하 | １형 당뇨병, ２형 당뇨병, 내당능 장애 또는 고혈당증을 치료하기 위한 ｓｇｌｔ２ 억제제 |
| DK2486029T3 (en) | 2009-09-30 | 2015-08-24 | Boehringer Ingelheim Int | Methods of making of glucopyranosyl-substituted benzyl-benzene derivatives. |
| ES2596202T3 (es) | 2009-09-30 | 2017-01-05 | Boehringer Ingelheim International Gmbh | Método para la preparación de una forma cristalina de 1-cloro-4-(ß-D-glucopiranos-1-il)-2-[4-((S)-tetrahidrofuran-3-iloxi)-bencil]-benceno |
| US10610489B2 (en) | 2009-10-02 | 2020-04-07 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, pharmaceutical dosage form, process for their preparation, methods for treating and uses thereof |
| US20120283169A1 (en) * | 2010-11-08 | 2012-11-08 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
| AR085689A1 (es) | 2011-03-07 | 2013-10-23 | Boehringer Ingelheim Int | Composiciones farmaceuticas de metformina, linagliptina y un inhibidor de sglt-2 |
| US9555001B2 (en) | 2012-03-07 | 2017-01-31 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition and uses thereof |
| US9192617B2 (en) | 2012-03-20 | 2015-11-24 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
| ES2959444T3 (es) | 2013-04-04 | 2024-02-26 | Boehringer Ingelheim Vetmedica Gmbh | Tratamiento de trastornos metabólicos en animales equinos |
| HRP20190101T1 (hr) | 2013-04-05 | 2019-03-08 | Boehringer Ingelheim International Gmbh | Terapeutske uporabe empagliflozina |
| CA2812519A1 (en) | 2013-04-05 | 2014-10-05 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
| CA2812016A1 (en) * | 2013-04-05 | 2014-10-05 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
| US20140303097A1 (en) | 2013-04-05 | 2014-10-09 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
| US11813275B2 (en) | 2013-04-05 | 2023-11-14 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
| PL2986304T3 (pl) | 2013-04-18 | 2022-05-02 | Boehringer Ingelheim International Gmbh | Kompozycja farmaceutyczna, sposoby leczenia i jej zastosowania |
| EP3082829B1 (en) * | 2013-12-17 | 2021-02-17 | Boehringer Ingelheim Vetmedica GmbH | Sglt2 inhibitors for the treatment of metabolic disorders in feline animals |
| EA032558B1 (ru) * | 2014-01-23 | 2019-06-28 | Бёрингер Ингельхайм Ветмедика Гмбх | Лечение метаболических расстройств у представителей собачьих |
| DK3721882T3 (da) | 2014-04-01 | 2024-10-21 | Boehringer Ingelheim Vetmedica Gmbh | Behandling af hypofyse pars intermedia-dysfunktion hos hestedyr |
| KR102539788B1 (ko) | 2014-09-25 | 2023-06-07 | 베링거잉겔하임베트메디카게엠베하 | 말과 동물의 대사 장애를 예방하기 위한 sglt2 억제제와 도파민 작용제의 병용 치료 |
| CN104473920A (zh) * | 2014-12-20 | 2015-04-01 | 长沙佰顺生物科技有限公司 | 一种用于治疗2型糖尿病的复方制剂及其制备方法 |
| MX389367B (es) | 2015-08-27 | 2025-03-20 | Boehringer Ingelheim Vetmedica Gmbh | Composiciones farmaceuticas liquidas que comprenden inhibidores de sglt-2. |
| WO2018087132A1 (en) | 2016-11-10 | 2018-05-17 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
| CN110092768A (zh) * | 2018-04-23 | 2019-08-06 | 中国科学院成都生物研究所 | 包含钠-葡萄糖协同转运蛋白1抑制剂的组合物及使用方法 |
| WO2021014351A1 (en) * | 2019-07-23 | 2021-01-28 | Novartis Ag | Treatment comprising sglt inhibitors, e.g. sglt 1/2 inhibitors |
| CN110327355B (zh) * | 2019-08-12 | 2021-06-04 | 浙江养生堂天然药物研究所有限公司 | 包含柠檬苦素类化合物和sglt-2抑制剂的组合产品 |
| EP4025197A4 (en) * | 2019-09-04 | 2023-09-13 | The Regents Of The University Of Michigan | SGLT INHIBITORS AND THEIR USES |
| US20210093698A1 (en) * | 2019-09-13 | 2021-04-01 | Sanofi | Treatment of type 2 diabetes mellitus |
| CN121604972A (zh) * | 2023-07-04 | 2026-03-03 | 宁波市瓦尔生物科技有限公司 | 一种控制血糖的药物组合试剂盒 |
Family Cites Families (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1213296B1 (en) | 1999-08-31 | 2004-04-14 | Kissei Pharmaceutical Co., Ltd. | Glucopyranosyloxypyrazole derivatives, medicinal compositions containing the same and intermediates in the production thereof |
| PH12000002657B1 (en) | 1999-10-12 | 2006-02-21 | Bristol Myers Squibb Co | C-aryl glucoside SGLT2 inhibitors |
| US6515117B2 (en) | 1999-10-12 | 2003-02-04 | Bristol-Myers Squibb Company | C-aryl glucoside SGLT2 inhibitors and method |
| WO2002044192A1 (en) | 2000-11-30 | 2002-06-06 | Kissei Pharmaceutical Co., Ltd. | Glucopyranosyloxybenzyl benzene derivatives, medicinal compositions containing the same and intermediates in the production thereof |
| SK287786B6 (sk) | 2000-12-28 | 2011-09-05 | Kissei Pharmaceutical Co., Ltd. | Glukopyranosyloxypyrazolový derivát, farmaceutická kompozícia alebo kombinácia s jeho obsahom a ich použitie |
| PL210710B1 (pl) | 2002-03-22 | 2012-02-29 | Kissei Pharmaceutical | Krystaliczne postaci 2-(4-metoksybenzylo) fenylo-6-O-etoksykarbonylo-ß-D-glukopiranozydu, ich zastosowanie oraz zawierająca je kompozycja farmaceutyczna |
| DE10231370B4 (de) | 2002-07-11 | 2006-04-06 | Sanofi-Aventis Deutschland Gmbh | Thiophenglycosidderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zur Herstellung dieser Arzneimittel |
| ATE510834T1 (de) | 2003-03-14 | 2011-06-15 | Astellas Pharma Inc | C-glykosid-derivate zur behandlung von diabetes |
| CN104109155A (zh) | 2003-08-01 | 2014-10-22 | 田边三菱制药株式会社 | 新颖化合物 |
| DE102004012676A1 (de) * | 2004-03-16 | 2005-10-06 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Glucopyranosyl-substituierte Phenyle, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung |
| EA011158B1 (ru) | 2004-03-16 | 2009-02-27 | Бёрингер Ингельхайм Интернациональ Гмбх | Замещённые глюкопиранозилом бензольные производные, содержащие эти соединения лекарственные средства, их применение и способ их получения |
| AR051446A1 (es) | 2004-09-23 | 2007-01-17 | Bristol Myers Squibb Co | Glucosidos de c-arilo como inhibidores selectivos de transportadores de glucosa (sglt2) |
| JP2008524162A (ja) | 2004-12-16 | 2008-07-10 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | グルコピラノシル置換ベンゼン誘導体、該化合物を含む薬物、その使用及びその製造方法 |
| UA91546C2 (uk) * | 2005-05-03 | 2010-08-10 | Бьорінгер Інгельхайм Інтернаціональ Гмбх | КРИСТАЛІЧНА ФОРМА 1-ХЛОР-4-(β-D-ГЛЮКОПІРАНОЗ-1-ИЛ)-2-[4-((S)-ТЕТРАГІДРОФУРАН-3-ІЛОКСИ)-БЕНЗИЛ]-БЕНЗОЛУ, СПОСІБ ЇЇ ОДЕРЖАННЯ ТА ЇЇ ЗАСТОСУВАННЯ ПРИ ПРИГОТУВАННІ ЛІКАРСЬКИХ ЗАСОБІВ |
| US7723309B2 (en) | 2005-05-03 | 2010-05-25 | Boehringer Ingelheim International Gmbh | Crystalline forms of 1-chloro-4-(β-D-glucopyranos-1-yl)-2-[4-((R)-tetrahydrofuran-3-yloxy)-benzyl]-benzene, a method for its preparation and the use thereof for preparing medicaments |
| US7772191B2 (en) | 2005-05-10 | 2010-08-10 | Boehringer Ingelheim International Gmbh | Processes for preparing of glucopyranosyl-substituted benzyl-benzene derivatives and intermediates therein |
| JP5175191B2 (ja) | 2005-08-30 | 2013-04-03 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | グリコピラノシル置換ベンジルベンゼン誘導体、該化合物を含有する医薬品及びその使用と製造方法 |
| BRPI0615882A2 (pt) | 2005-09-08 | 2011-05-31 | Boehringer Ingelheim Int | formas cristalinas de 1-cloro-4-(beta-d-glicopiranos-1-il)-2-(4-etinil-benzil)- benzeno, métodos para sua preparação e o uso para preparar medicamentos do mesmo |
| AR056195A1 (es) | 2005-09-15 | 2007-09-26 | Boehringer Ingelheim Int | Procedimientos para preparar derivados de (etinil-bencil)-benceno sustituidos de glucopiranosilo y compuestos intermedios de los mismos |
| AR059489A1 (es) | 2006-02-15 | 2008-04-09 | Boehringer Ingelheim Vetmed | Derivados de benzonitrilo sustituidos con glucopiranosilo, composiciones farmaceuticas que contienen compuestos de este tipo, su uso y procedimiento para su fabricacion |
| TWI370818B (en) | 2006-04-05 | 2012-08-21 | Astellas Pharma Inc | Cocrystal of c-glycoside derivative and l-proline |
| PE20080697A1 (es) | 2006-05-03 | 2008-08-05 | Boehringer Ingelheim Int | Derivados de benzonitrilo sustituidos con glucopiranosilo, composiciones farmaceuticas que contienen compuestos de este tipo, su uso y procedimiento para su fabricacion |
| WO2007140191A2 (en) | 2006-05-23 | 2007-12-06 | Theracos, Inc. | Glucose transport inhibitors and methods of use |
| US7919598B2 (en) | 2006-06-28 | 2011-04-05 | Bristol-Myers Squibb Company | Crystal structures of SGLT2 inhibitors and processes for preparing same |
| DE102006031962A1 (de) | 2006-07-11 | 2008-01-17 | Sanofi-Aventis Deutschland Gmbh | Amidiertes Insulin Glargin |
| TWI403516B (zh) | 2006-07-27 | 2013-08-01 | Chugai Pharmaceutical Co Ltd | To replace spirocyclic alcohol derivatives, and its use as a therapeutic agent for diabetes |
| CA2656847A1 (en) | 2006-08-15 | 2008-02-21 | Boehringer Ingelheim International Gmbh | Glucopyranosyl-substituted cyclopropylbenzene derivatives, pharmaceutical compositions containing such compounds, their use as sglt inhibitors and process for their manufacture |
| US8283326B2 (en) | 2006-10-27 | 2012-10-09 | Boehringer Ingelheim International Gmbh | Crystalline form of 4-(beta-D-glucopyranos-1-yl)-1-methyl-2-[4-((S)-tetrahydrofuran-3-yloxy)-benzyl]-benzene, a method for its preparation and the use thereof for preparing medicaments |
| AR063569A1 (es) | 2006-11-06 | 2009-02-04 | Boehringer Ingelheim Int | Derivados de benzil- benzonitrilo sustituidos con glucopiranosilo medicamentos que contienen a compuestos de este tipo su uso u procedimiento para su fabricacion |
| CL2007003227A1 (es) * | 2006-11-09 | 2008-07-04 | Boehringer Ingelheim Int | Composicion farmaceutica que comprende un derivado de benceno sustituido con glucopiranosilo en combinacion con uno o mas agentes terapeuticos; y uso para el tratamiento de diabetes mellitus, obesidad e hiperglucemia entre otras. |
| UY30730A1 (es) | 2006-12-04 | 2008-07-03 | Mitsubishi Tanabe Pharma Corp | Forma cristalina del hemihidrato de 1-(b (beta)-d-glucopiranosil) -4-metil-3-[5-(4-fluorofenil) -2-tienilmetil]benceno |
| TW200904405A (en) | 2007-03-22 | 2009-02-01 | Bristol Myers Squibb Co | Pharmaceutical formulations containing an SGLT2 inhibitor |
| MX2010002695A (es) | 2007-09-10 | 2010-04-01 | Janssen Pharmaceutica Nv | Proceso para la preparacion de compuestos utiles como inhibidores de transportador de glucosa dependiente de sodio (sglt). |
| KR20100111683A (ko) | 2008-01-09 | 2010-10-15 | 사노피-아벤티스 도이칠란트 게엠베하 | 극히 지연된 시간-작용 프로필을 갖는 신규 인슐린 유도체 |
| RU2524423C2 (ru) | 2008-01-09 | 2014-07-27 | Санофи-Авентис Дойчланд Гмбх | Новые производные инсулина с чрезвычайно замедленным профилем время/действие |
| CN101503399B (zh) * | 2008-02-04 | 2012-06-27 | 白鹭医药技术（上海）有限公司 | C-芳基葡萄糖苷sglt2抑制剂 |
| TWI451876B (zh) | 2008-06-13 | 2014-09-11 | Lilly Co Eli | 聚乙二醇化之離脯胰島素化合物 |
| US20110014284A1 (en) | 2009-02-13 | 2011-01-20 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, pharmaceutical dosage form, process for their preparation, methods for treating and uses thereof |
| KR20110118668A (ko) | 2009-02-13 | 2011-10-31 | 베링거 인겔하임 인터내셔날 게엠베하 | １형 당뇨병, ２형 당뇨병, 내당능 장애 또는 고혈당증을 치료하기 위한 ｓｇｌｔ２ 억제제 |
| UY32427A (es) | 2009-02-13 | 2010-09-30 | Boheringer Ingelheim Internat Gmbh | Composicion farmaceutica, forma farmaceutica, procedimiento para su preparacion, metodos de tratamiento y usos de la misma |
| AR076317A1 (es) * | 2009-04-16 | 2011-06-01 | Taisho Pharmaceutical Co Ltd | Composiciones farmaceuticas que comprenden un compuesto de 1-tio-d-glucitol. |
| CN106075451A (zh) * | 2009-05-27 | 2016-11-09 | 阿斯利康(瑞典)有限公司 | 使用sglt2抑制剂及其组合物在对先前用其它抗糖尿病药进行的治疗具有耐受的患者中治疗ii型糖尿病的方法 |
| JP2013523681A (ja) * | 2010-03-30 | 2013-06-17 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｓｇｌｔ２インヒビター及びｐｐａｒ−ガンマアゴニストを含む医薬組成物並びにその使用 |
| US20120283169A1 (en) | 2010-11-08 | 2012-11-08 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
| JP5876170B2 (ja) * | 2015-01-13 | 2016-03-02 | 株式会社平和 | 遊技機 |
-
2011
- 2011-11-02 US US13/287,216 patent/US20120283169A1/en not_active Abandoned
- 2011-11-07 PE PE2013000955A patent/PE20140244A1/es not_active Application Discontinuation
- 2011-11-07 CA CA2813661A patent/CA2813661C/en active Active
- 2011-11-07 BR BR112013011968A patent/BR112013011968A2/pt not_active IP Right Cessation
- 2011-11-07 SI SI201132125T patent/SI3539540T1/sl unknown
- 2011-11-07 JP JP2013537158A patent/JP2013541576A/ja active Pending
- 2011-11-07 CN CN201180064091XA patent/CN103282030A/zh active Pending
- 2011-11-07 FI FIEP19163940.0T patent/FI3539540T3/fi active
- 2011-11-07 EA EA201300550A patent/EA026712B1/ru not_active IP Right Cessation
- 2011-11-07 CN CN201610579791.7A patent/CN106177957A/zh active Pending
- 2011-11-07 WO PCT/EP2011/069532 patent/WO2012062698A1/en not_active Ceased
- 2011-11-07 NZ NZ608829A patent/NZ608829A/en unknown
- 2011-11-07 AR ARP110104151A patent/AR083787A1/es unknown
- 2011-11-07 SG SG2013024849A patent/SG189249A1/en unknown
- 2011-11-07 EP EP11778916.4A patent/EP2637648A1/en not_active Withdrawn
- 2011-11-07 EP EP19163940.0A patent/EP3539540B1/en active Active
- 2011-11-07 KR KR1020187022985A patent/KR102051285B1/ko active Active
- 2011-11-07 KR KR1020197034873A patent/KR102232451B1/ko active Active
- 2011-11-07 KR KR1020137011966A patent/KR20130125365A/ko not_active Ceased
- 2011-11-07 PH PH1/2013/500809A patent/PH12013500809A1/en unknown
- 2011-11-07 HU HUE19163940A patent/HUE070541T2/hu unknown
- 2011-11-07 LT LTEP19163940.0T patent/LT3539540T/lt unknown
- 2011-11-07 AP AP2013006813A patent/AP2013006813A0/xx unknown
- 2011-11-07 MX MX2013005095A patent/MX356491B/es active IP Right Grant
- 2011-11-07 AU AU2011328231A patent/AU2011328231B2/en active Active
- 2011-11-07 PL PL19163940.0T patent/PL3539540T3/pl unknown
- 2011-11-07 ES ES19163940T patent/ES3012504T3/es active Active
- 2011-11-07 HR HRP20250096TT patent/HRP20250096T1/hr unknown
- 2011-11-07 DK DK19163940.0T patent/DK3539540T3/da active
- 2011-11-07 MX MX2018006655A patent/MX374694B/es unknown
- 2011-11-07 RS RS20250115A patent/RS66479B1/sr unknown
-
2013
- 2013-04-07 IL IL225597A patent/IL225597A0/en unknown
- 2013-04-22 CL CL2013001104A patent/CL2013001104A1/es unknown
- 2013-05-02 MA MA35865A patent/MA34640B1/fr unknown
- 2013-05-08 CO CO13115446A patent/CO6781465A2/es not_active Application Discontinuation
- 2013-06-04 EC ECSP13012661 patent/ECSP13012661A/es unknown
-
2014
- 2014-01-17 US US14/157,678 patent/US20140256624A1/en not_active Abandoned
-
2015
- 2015-05-15 JP JP2015100121A patent/JP6141907B2/ja active Active
-
2017
- 2017-02-06 JP JP2017019822A patent/JP6515121B2/ja active Active
-
2018
- 2018-03-08 US US15/915,396 patent/US20180193427A1/en not_active Abandoned
- 2018-04-06 PH PH12018500767A patent/PH12018500767A1/en unknown
-
2020
- 2020-03-18 US US16/822,360 patent/US20200397867A1/en not_active Abandoned
-
2021
- 2021-08-12 US US17/400,221 patent/US20220152159A1/en not_active Abandoned
-
2024
- 2024-06-18 US US18/746,567 patent/US20240335514A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Kann et al. | Starting insulin therapy in type 2 diabetes: twice-daily biphasic insulin Aspart 30 plus metformin versus once-daily insulin glargine plus glimepiride | |
| MX2011007371A (es) | Metodo para tratar la hiperglucemia con la molecula. | |
| Mokta et al. | Insulin lipodystrophy and lipohypertrophy | |
| FI3539540T3 (fi) | Sglt2:n estäjä 1-kloori-4-(beta-d-glukopyranos-1-yyli)-2-[4-((s)-tetrahydrofuran-3-yylioksi)bentsyyli]bentseeni yhdessä insuliinin kanssa käytettäväksi menetelmässä hypoglykemiariskin vähentämiseksi | |
| Enginyurt et al. | The role of pure honey in the treatment of diabetes mellitus | |
| Joshi et al. | Designer insulins regimens in clinical practice-pilot multicenter Indian study | |
| Ghosal et al. | Insulin glargine versus insulin degludec in patients failing on oral therapy in type 2 diabetes: a retrospective real world comparative data from India | |
| Chakraborty et al. | Distant site lipoatrophy: a rare complication of subcutaneous insulin therapy | |
| Kara et al. | Efficacy and Safety of Sirolimus (mTOR Inhibitor) in Two Patients with Diazoxide-Unresponsive Hyperinsulinemic Hypoglycemia. | |
| WO2012141764A3 (en) | Pre-operative use of metabolic activation therapy | |
| Triplitt | Cardiac risk factors and hypoglycemia in an elderly patient: how good is good enough? | |
| Vinik | Benefits of early initiation of insulin therapy to long-term goals in type 2 diabetes mellitus | |
| Annabestani et al. | Insulin buccal spray (Oral-Lyn) efficacy in type 1 diabetes | |
| Hompesch et al. | Glycemic exposure is affected favorably by inhaled human insulin (Exubera) as compared with subcutaneous insulin glargine (Lantus) in patients with type 2 diabetes | |
| Tarigan et al. | Strategy of insulin intensification after basal failure for type 2 diabetes in the outpatient setting | |
| Striano et al. | Hemidystonia in uncontrolled type 2 diabetes mellitus | |
| Cao | Diabetic ketoacidosis: case report | |
| Ridderstråle et al. | Empagliflozin (EMPA) compared with glimepiride (GLIM) as add-on to metformin (MET) for 2 years in patients with type 2 diabetes (T2DM) | |
| KK et al. | Prevalence of Diabetic Retinopathy and Associated Factors in Type 2 Diabetes in a Tertiary Care Centre in Kannur District of Kerala | |
| Lehman et al. | No to QOF target of less than 7%, again | |
| M Junaid et al. | Comorbidities in patients requiring dental extraction | |
| de Vries | Is an insulin pump not superior to injections for children with newly discovered diab. | |
| Chang | Diabetic muscle infarction: case report | |
| de Bie | 30 An latrogenic Catatonia | |
| Bilal Abdul Qayum et al. | Improving quality of life of diabetic patients through non-surgical periodontal treatment |